Swine Pneumonia Market was valued at USD 218.6 billion in 2020, and is expected to reach USD 317.4 billion by 2027, supported by a CAGR of 9.8% during the forecast period 2020 to 2027.
“Pneumonia” means inflammation of the lungs. It may be minor, subsiding quickly, or develop into advanced pneumonia. The cause of the lung inflammation and the development of complications, such as secondary bacterial infection, generally determine how severe pneumonia becomes. Coughing and “thumping” (shallow, rapid breathing) are typical symptoms of pneumonia in swine. As the pneumonia becomes more severe, appetite and growth rate decrease, feed is utilized less efficiently, hogs may become chronic poor-doers, death may occur and treatment and control costs escalate
Respiratory disease in pigs has been a cause of substantial mortality and economic burden or the swine industry. Particularly, according to a statistics, swine respiratory diseases involve multiple infectious agents, and have been one of the key causes of death in nursery pigs. Various prevention strategies, notably All-In-All-Out (AIAO) swine production system in the U.S., have failed to meet the profitability expectations of the swine industry. This has invigorated research on the aetiology of pneumonic swine’s lungs—the main agent being mycoplasma hyopneumoniae.
Growing awareness about the health of swine among pork consumers has spurred research on pig's protection mechanisms, thereby encouraging the growth of the swine respiratory diseases treatment market. The primary pathogens under scanner are porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus, and porcine circovirus type 2. A great deal of research has come with an aim to persistence of PRRSV in swine herds in various countries.
Modern methods of treatment usually comprise stressing on herd diagnostics and preventative measures for swine producers. Antibiotics and vaccinations comprise key arsenal in modern management strategies in the swine respiratory diseases treatment market. Adoption of new pathogen eradication schemes have emphasized on environmental and management conditions to understand the risk factors for porcine respiratory disease complex. New treatment avenues increasingly focus on secondary or opportunistic pathogens responsible for porcine respiratory disease complex. New approaches to control disease development, notably increasing host immunity to pathogens, are likely to see good uptake among swine producers in various parts of the world.
“Pneumonia” means inflammation of the lungs. It may be minor, subsiding quickly, or develop into advanced pneumonia. The cause of the lung inflammation and the development of complications, such as secondary bacterial infection, generally determine how severe pneumonia becomes. Coughing and “thumping” (shallow, rapid breathing) are typical symptoms of pneumonia in swine. As the pneumonia becomes more severe, appetite and growth rate decrease, feed is utilized less efficiently, hogs may become chronic poor-doers, death may occur and treatment and control costs escalate
Respiratory disease in pigs has been a cause of substantial mortality and economic burden or the swine industry. Particularly, according to a statistics, swine respiratory diseases involve multiple infectious agents, and have been one of the key causes of death in nursery pigs. Various prevention strategies, notably All-In-All-Out (AIAO) swine production system in the U.S., have failed to meet the profitability expectations of the swine industry. This has invigorated research on the aetiology of pneumonic swine’s lungs—the main agent being mycoplasma hyopneumoniae.
Growing awareness about the health of swine among pork consumers has spurred research on pig's protection mechanisms, thereby encouraging the growth of the swine respiratory diseases treatment market. The primary pathogens under scanner are porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus, and porcine circovirus type 2. A great deal of research has come with an aim to persistence of PRRSV in swine herds in various countries.
Modern methods of treatment usually comprise stressing on herd diagnostics and preventative measures for swine producers. Antibiotics and vaccinations comprise key arsenal in modern management strategies in the swine respiratory diseases treatment market. Adoption of new pathogen eradication schemes have emphasized on environmental and management conditions to understand the risk factors for porcine respiratory disease complex. New treatment avenues increasingly focus on secondary or opportunistic pathogens responsible for porcine respiratory disease complex. New approaches to control disease development, notably increasing host immunity to pathogens, are likely to see good uptake among swine producers in various parts of the world.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
